Login / Signup

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.

Yasutoshi KubokiToshio ShimizuKan YonemoriTakashi KojimaShunsuke KondoShigehiro KoganemaruSatoru IwasaKenichi HaranoTakafumi KoyamaVickie LuXiaofei ZhouHuifeng NiuTomoko YanaiIgnacio Garcia-RibasToshihiko DoiNoboru Yamamoto
Published in: Cancer research communications (2022)
This was the first-in-human study of the CDC7 inhibitor, TAK-931, in patients with solid tumors. TAK-931 was generally tolerable with a manageable safety profile. The recommend phase II dose was determined to be TAK-931 50 mg administered once daily on days 1-14 of each 21-day cycle. A phase II study is ongoing to confirm the safety, tolerability, and antitumor activity of TAK-931 in patients with metastatic solid tumors.
Keyphrases
  • open label
  • phase ii
  • phase ii study
  • endothelial cells
  • clinical trial
  • placebo controlled
  • induced pluripotent stem cells
  • stem cells
  • radiation therapy
  • single cell
  • pluripotent stem cells
  • double blind